Pathway-specific, species, and sub-type counterscreening for better GPCR hits in high throughput screening

Robert Swanson1, James R Beasley

  • 1Ligand Pharmaceuticals, 3000 Eastpark Blvd., Cranbury, NJ 08512, USA.

Summary

Early assessment of G protein-coupled receptor (GPCR) modulators for signaling and species selectivity can save time and cost in drug discovery. Evaluating selectivity during high-throughput screening is key for efficient development.